Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies
Company to be based in Houston with first round funding of $60 million
MD Anderson News Release 08/26/2015
Immatics Biotechnologies GmbH (Immatics) and The University of Texas MD Anderson Cancer Center announced today the launch of Immatics US, Inc., a new company aiming at becoming a global leader in adoptive cellular therapies (ACT) for the treatment of a range of tumor types.
Immatics believes that...
Internationally recognized leader to direct Moon Shots Program prevention efforts
MD Anderson News Release 08/26/2015
The University of Texas MD Anderson Cancer Center has appointed former U.S. Public Health Service...
MD Anderson to host evening fun run supporting skin cancer research
MD Anderson News Release 08/26/2015
Runners and walkers will soon hit the streets for the eighth annual AIM for the CURE Melanoma...
Generic heart medication shown to prolong ovarian cancer patients’ survival
Even despite prognostic factors and co-morbidities associated with poorer outcomes
MD Anderson News Release 08/23/2015
In a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer (EOC) patients receiving generic heart medications known as beta-blockers. Survival was shown to be greatest among those prescribed first-generation nonselective beta-blockers. According...
UTMB, MD Anderson to collaborate on League City campus
MD Anderson News Release 08/20/2015
The University of Texas Medical Branch at Galveston and The University of Texas MD Anderson Cancer...
MD Anderson to build new outpatient center in West Houston
MD Anderson News Release 08/20/2015
With the approval of The University of Texas System Board of Regents today, The University of Texas...
MD Anderson study reveals new insight into tumor progression
Regulation of tumor ‘microenvironment’ may offer alternate approach for treatment
MD Anderson News Release 08/17/2015
Merck and MD Anderson announce immuno-oncology research collaboration in solid tumors
Clinical trials to evaluate Merck’s KEYTRUDA® (pembrolizumab) in combination with other medicines and treatments across multiple tumor types...
Helping preschoolers deploy ‘superpowers’ against sunburn
Ray and the Sunbeatables™ debut through CATCH; arise from MD Anderson research
MD Anderson News Release 08/12/2015
Five...
MD Anderson names Valerae O. Lewis, M.D., chair of Orthopaedic Oncology
Dr. Lewis is internationally recognized for her expertise in pelvic sarcoma surgery and substantial contributions in shaping orthopaedic education...
Poor survival among colorectal cancer patients tied to biomarker CSN6
MD Anderson News Release 08/10/2015
A protein called CSN6 has been found to be correlated with poor survival among patients...
Shorter course of radiation therapy associated with less toxicity, improved quality of life in women with early stage breast cancer
MD Anderson researchers recommend hypofractionated treatment as a starting point for treatment discussion between patients, physicians...
Potential new therapy approaches to reverse kidney damage identified
Study shows that cell plasticity program resulting from kidney damage can be targeted to reverse disease and fibrosis.
MD Anderson...
MD Anderson study reveals new insight into DNA Repair
The enzyme fumarase key to reversing genetic damage leading to cancer and therapy resistance
MD Anderson News Release 08/03/2015<...